Next generation point-of-care analytics

NEW POSSIBILITIES FOR HEALTHCARE

We’re enabling healthcare professionals to measure the real blood concentration of paracetamol, opioids and other pain medicine directly from a drop of blood at the point-of-care. Our testing process is fast & simple and the result is available in seconds. Our testing equipment consists of a standard mobile phone, an affordable & small potentiostat and mass-producible & disposable sampling sensors.

 

Our technology has been under research and constant development in Aalto University for years and it has been shown to be able identify the targeted opioids and paracetamol from human blood. Further testing, clinical trials at the HUS (Helsinki University hospital) and sensor development are ongoing.​

 

We’re certain that this novel and portable analytics method will open a lot of new possibilities for healthcare.​

BUSINESS MODEL

Our business model is a combination of licensing the technology to subcontractors & clients and providing the machine learning based analytics software using the SaaS-model (white label & own brand).​

 

All the anonymous analytics data will be owned by us to allow the machine learning algorithms continuously improve as the database grows.​

 

Revenue is generated from manufacturing license deals (fixed fees & royalties), commercial license deals (fixed fees, milestone payments & royalties) and SaaS-service fees (fixed fees & analysis based).

 

We’re opening discussions with potential clients and looking forward in starting common projects to get our solution into the market in the near future.

NEW POSSIBILITIES FOR HEALTHCARE

We’re enabling healthcare professionals to measure the real blood concentration of paracetamol, opioids and other pain medicine directly from a drop of blood at the point-of-care. Our testing process is fast & simple and the result is available in seconds. Our testing equipment consists of a standard mobile phone, an affordable & small potentiostat and mass-producible & disposable sampling sensors.

 

Our technology has been under research and constant development in Aalto University for years and it has been shown to be able identify the targeted opioids and paracetamol from human blood. Further testing, clinical trials at the HUS (Helsinki University hospital) and sensor development are ongoing.​

 

We’re certain that this novel and portable analytics method will open a lot of new possibilities for healthcare.​

BUSINESS MODEL

Our business model is a combination of licensing the technology to subcontractors & clients and providing the machine learning based analytics software using the SaaS-model (white label & own brand).​

 

All the anonymous analytics data will be owned by us to allow the machine learning algorithms continuously improve as the database grows.​

 

Revenue is generated from manufacturing license deals (fixed fees & royalties), commercial license deals (fixed fees, milestone payments & royalties) and SaaS-service fees (fixed fees & analysis based).

 

We’re opening discussions with potential clients and looking forward in starting common projects to get our solution into the market in the near future.

OUR SOLUTION

Simplefast and 
relatively painless finger prick sampling on our patented sensor.

 

Sensor is inserted in a portable potentiostat connected to mobile phone.

 

The results are available almost immediately and transferred securely to  our servers for analysis.

 

Our machine learning servers process the results and return the analysis to the user.

 

SUCCESS STORIES

We recently demonstrated large-scale roll-to-roll compatible production of our electrochemical test strips for the detection of paracetamol analgesics in whole blood.

 

The fast transition from lab to fab is possible due to our tight R&D partnership with Canatu Ltd that has developed a roll-to-roll production process for CNBTM-sensors.

 

In a recent publication in ACS analytical chemistry, this sensor was used to develop an assay for quantitative point-of-care detection of paracetamol (acetaminophen) from finger-prick whole blood in less than 5 min.

Our prototype sensors were being validated in a small-scale human study.


In this study paracetamol was administered to 12 healthy volunteers and the paracetamol concentration was determined at several timepoints from finger-prick blood samples, saliva and venous blood.


The study aimed at showing close to real time quantitative detection of paracetamol after single oral dose.


The final results are being validated and will be published later this year.


Read more at ClinicalTrials.gov.

In the second study we have collected 200 samples from patients with suspected paracetamol intoxication.

 

These samples are being analyzed with our prototype equipment in parallel with validated laboratory tests from two separate laboratories.

 

In both of our early clinical studies the results are compared to liquid chromatography–mass spectrometry (LC–MS).

 

The initial results of this study are looking very promising.

INVESTORS AND CAREERS

After running the project last few years at the Aalto University with R2B funding from Business Finland our start-up was incorporated in February 2022.

 

During the spring of 2022 we were able to close required seed investments. These private investments combined with governmental grants and loans should get us over the next clinical tests, close the first licensing deals and finalize the commercial test kits and the software platform (mobile app & cloud-based machine learning system).

 

We strongly believe that our proven and protected technology, great team, the targeted multi-billion market, huge customer value, clear market traction and multiple logical exit options will be enough to convince both private and governmental investors in the future too.

We currently have a five-person founder team, advisors from Aalto University & Helsinki University hospital and a committed manufacturer (Canatu Ltd) for our sensors.​

 

We were recently accepted into the Health Incubator Helsinki -program. This unique long-term business development environment for research-based health sector startups helps us by providing a home base in Meilahti, targeted training and peer support.

 

For new recruits we’re offering a fast-growing, born global deep tech start-up that’ll make a difference in the diagnostics market. We’re also reserving a notable option pool for our key recruits and for the board & advisors.​

CONTACT

    Jussi Pyysalo

    Founder & CEO

    jussi.pyysalo@fepod.com

    +358 400 789328

    Elsi Verrinder, D.Sc. 

    Co-founder & CSO

    elsi.verrinder@fepod.com

    +1 805 2947063

    Niklas Wester, D.Sc. 

    Founder & CTO

    niklas.wester@fepod.com

    +358 50 460 2743